arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

LIGAND PHARMACEUTICALS INC

LGND
$298.24 ▼ -0.63 (-0.21%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
68 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
77
Health
Good
Bullish
auto_awesome

Analytical Summary

LIGAND PHARMACEUTICALS INC shows strong fundamentals with top-quartile Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $6.0B
Dividend Yield
Revenue Growth 33.7%
Op. Margin 13.5%
ROIC 0.3%
FCF / Share $1.20
Trailing P/E 123.2x
Price / Book 6.1x
FCF Yield 0.4%
Debt / Equity 1.16
info Valuation on last close. End-of-day price, Sep 23, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$63.69M
↑ +33.7%
Net Income Profit after all expenses
$-13.35M
↑ +68.6%
Operating Margin Operating profit as % of sales
13.5%
↓ -59.8% 67th
FCF / Share Free cash flow per share
$1.20
↓ -50.9%
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
82
Returns
74
Financial Health
96
Cash Quality
36

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 19 years · 68 quarters